Answer

Is the estrogen patch safer than pills? (Transdermal vs oral)

HRT & Menopause hrt estrogen safety menopause

Verdict

Strong consensus for

Transdermal estrogen carries a lower clot risk than oral estrogen.

+4 20 sources: 18 positive, 2 negative

20 sources: 18 positive, 2 negative

By Arun AgrahriLast reviewed

Based on what researchers say in public interviews on YouTube. Educational only, not medical advice. Ask a qualified clinician before changing a supplement, medication, treatment, or testing plan.

Short answer

Yes, for clot risk. Wherever a preference is stated, it is transdermal: a patch, a gel or a spray. Estradiol through the skin skips the liver first-pass that drives oral estrogen's clot risk (VTE, stroke) and gallbladder risk. It is paired with micronized progesterone if you have a uterus. Route is your clinician's call.

Leaning for

Hormone therapy around menopause does more good than harm for most women.

The verdict on HRT & Menopause overall. 12 sources: 4 positive, 8 partly

What the evidence says

positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.

  1. Strong consensus for

    Transdermal estrogen carries a lower clot risk than oral estrogen.

    20 sources: 18 positive, 2 negative.

    Researchers say

    3 positive

    Studies show

    15 positive, 2 negative

    16 papers we read · 1 cited on tape, not yet checked against the paper

    17 more not counted · see why
    The study is not yet read in full. 9
    We could not confirm who is speaking. 4
    The study cited could not be identified. 2
    A host's remark inside an interview. 1
    We could not tell what position it takes on this claim. 1
    Show the receipts from 20 sources

    1. Dr. Mary Claire Haver Video · positive · 3 mentions

      on Huberman Lab, at 34:20 · positive · Opinion

      “transdermal has less risk of blood clots versus oral has a higher risk of blood clot”

      on Huberman Lab, at 1:21:26 · positive · Opinion

      “for that reason I tend to go with the non-oral formulations to avoid that risk”

      on The Diary Of A CEO, at 52:47 · positive · Opinion

      “then we bypass the liver and we don't have the increased risk of clotting”

    2. Cynthia Guyer, on The Dr. Hyman Show, at 18:33 Video · positive · Opinion

      “you're not going to have those same risks for clotting”

    3. Gayatri Devi, on The Drive, at 1:49:49 Video · positive · Opinion

      “lower risk in my in my um for me the big consideration is lower risk of uh uh strokes and um uh Venus clots.”

    4. KEEPS, cited on The Drive, at 1:21:17 Study · positive

      “there's a slight increase of blood clots, right, with with oral estrogen”

    5. Trial or observed group, Lancet, 2003, PMID 12927428 Study · positive

      Estimated risk for VTE in current users of oral ERT compared with transdermal ERT users was 4.0 (1.9-8.3).

    6. Trial or observed group, Circulation, 2005, PMID 16301339 Study · positive

      Oral but not transdermal estrogen was associated with an increased risk of VTE (odds ratio [OR], 4.3; 95% CI, 2.6 to 7.2; and OR, 1.2; 95% CI, 0.8 to 1.7, respectively).

    7. Trial or observed group, J Thromb Haemost, 2006, PMID 16706969 Study · positive

      Oral, not transdermal, estrogen was associated with an increased VTE risk (OR = 4.5; 95% CI: 2.6-7.7 and OR = 1.1; 95% CI: 0.7-1.7, respectively).

    8. Trial or observed group, Circulation, 2007, PMID 17309934 Study · positive

      Oral but not transdermal estrogen is associated with an increased VTE risk.

    9. Other primary study, Arterioscler Thromb Vasc Biol, 2010, PMID 19834106 Study · positive

      Oral not transdermal estrogens were associated with increased thrombotic risk (HR=1.7; 95% CI: 1.1 to 2.8 and HR=1.1; 95% CI: 0.8 to 1.8; homogeneity: P=0.01).

    10. Other primary study, J Thromb Haemost, 2010, PMID 20230416 Study · positive

      The risk of VTE was not increased with current use of transdermal estrogen alone (RR 1.01; 95% CI, 0.89-1.16) or combined with a progestogen (RR 0.96; 95% CI, 0.77-1.20), or with current use of tibolone (RR 0.92; 95% CI: 0.77-1.10), relative to non-use.

    11. Other primary study, Menopause, 2011, PMID 21178641 Study · positive

      Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women.

    12. Other primary study, Menopause, 2011, PMID 21775912 Study · positive

      After adjustment for confounding factors, the incidence of venous thromboembolism remained significantly lower for estradiol transdermal system users than for estrogen-only hormone therapy users.

    13. Other primary study, J Thromb Haemost, 2012, PMID 22963114 Study · positive

      RRs in current vs. never users at last reporting varied by HT formulation: the risk was significantly greater for oral estrogen-progestin than oral estrogen-only therapy (RR = 2.07 [95%CI, 1.86-2.31] vs. 1.42 [1.21-1.66]), with no increased risk with transdermal estrogen-only therapy (0.82 [0.64-1.06]).

    14. Trial or observed group, J Thromb Haemost, 2013, PMID 23136837 Study · positive

      Non-oral HT did not increase the risk of VT: OR 1.1 (0.6-1.8).

    15. Trial or observed group, BMJ, 2019, PMID 30626577 Study · positive

      Use of oral preparations was associated with a significantly increased VTE risk (1.58, 1.52 to 1.64), whereas transdermal HRT was not associated with VTE risk (0.93, 0.87 to 1.01; table 2 ).

    16. Other primary study, Climacteric, 2022, PMID 36218141 Study · positive

      The risk of PE was significantly increased in users of oral but not transdermal MHT, with the highest risk in first ever users of oral estrogen combined with medroxyprogesterone acetate.

    17. Other primary study, Res Pract Thromb Haemost, 2023, PMID 37193125 Study · positive

      In a comparison between oral and transdermal exposures ( Table 4 shows direct comparisons between treatments), the ORs for oral exposures were almost twice as high as transdermal exposures (estrogen-only OR = 1.90; 95% CI, 1.56-2.32; combined therapy OR = 1.92; 95% CI, 1.43-2.60).

    18. Other primary study, BMJ, 2026, PMID 42778212 Study · positive

      No increased thrombotic risks were observed with transdermal therapy.

    19. Other primary study, Menopause, 2021, PMID 34313612 Study · negative

      Our study among women Veterans did not confirm previously observed differences in the risk of VTE associated with HT, comparing oral CEE, oral E2 and transdermal E2.

    20. Other primary study, BMJ, 1997, PMID 9081000 Study · negative

      No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations.

Where the sources disagree

Strong consensus for

Transdermal estrogen carries a lower clot risk than oral estrogen.

Supports it 18 sources

Researchers

Studies

Against it 2 sources

Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent

Detailed Answer

Transdermal estrogen carries a lower clot risk than oral estrogen. Wherever a preference is stated, it points the same way: a patch, a gel or a spray rather than a tablet. The reason is mechanical.

A pill goes through the gut and hits the liver first. That first pass raises clotting factors, and it ties oral estrogen to venous thromboembolism (VTE, a blood clot in a vein), stroke and gallbladder disease.

Through the skin

Estradiol on the skin skips most of that first pass, and clot risk falls with it. Peter Attia describes the modern approach as an estradiol patch, paired with micronized progesterone or a progesterone IUD if you still have a uterus. Mark Hyman picks skin delivery over oral to cut inflammation and clot risk, and bioidentical estradiol over the older Premarin/Provera pairing.

Mary Claire Haver, a guest on Andrew Huberman's show, is explicit that the patch carries less clot risk than the pill.

Two things alongside it

If you have a uterus, systemic estrogen comes with progesterone to protect the uterine lining. That is why the FDA kept its endometrial-cancer warning on systemic estrogen-only therapy. Also be careful with products sold next to real HRT, such as anti-aging hormone schemes with no trial behind them.

Views differ on compounded hormones and saliva testing: Hyman uses saliva tests and compounded creams in his own practice. See a qualified menopause specialist.

Route, formulation and dose are your doctor's call. This page explains why the patch usually wins; it is not a prescription.

Related Questions

Why is the estrogen patch considered safer than pills?
Oral estrogen passes through the liver first, which raises clotting factors. Those drive the VTE, stroke and gallbladder risks. Transdermal estradiol largely bypasses that liver pass, which is why the patch or gel is favored.
Do you still need progesterone with the estrogen patch?
Yes, if you have a uterus. Systemic estradiol is paired with micronized progesterone (or a progesterone IUD) to protect the uterine lining. The FDA kept the endometrial-cancer warning for estrogen-only therapy for this reason.
Are bioidentical hormones better than synthetic?
Bioidentical estradiol and micronized progesterone are favored over the older synthetic pairing (Premarin/Provera). Views on compounded hormones and saliva testing differ, and Hyman uses both. Get care from a qualified menopause specialist.

More Questions About HRT & Menopause

Is HRT safe now? What the FDA change and the ev... When should you start HRT - and can you start i... Does HRT cause breast cancer? What the numbers ... Is vaginal estrogen safe?

Precis membership

Get the exact protocol for HRT & Menopause

The answer above is the whole answer: the verdict, every counted mention, where the sources disagree, and the receipt behind each one. Nothing on this page is held back.

A free account adds

  • Each dose named on the record, and the form named with it
  • Timing, and what to take it with or keep it away from
  • The interactions flagged by name

Pro adds

  • Chat answers drawn from 3,700+ hours of recorded interviews with 380 researchers and doctors, plus 48,500+ research studies, each with a timecode
Go Pro — $9/mo or $79/yr

Full HRT & Menopause evidence report

The verdict on every claim, and where the sources disagree

How Precis checks a claim · Report an error

All answers